We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In-vivo Efficacy Profile of Decitabine

News   Apr 15, 2008

 
SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In-vivo Efficacy Profile of Decitabine
 
 
 

RELATED ARTICLES

Early Benefit Assessment Exposes Weaknesses in the Development of New Drugs

News

More than half of the drugs that have entered the market in Germany since then have emerged from these assessments without any proven added benefit. In a new publication using the first 216 assessments, researchers examine the reasons for this sobering result and develop suggestions for improvements in drug development.

READ MORE

Clinical Trial for New Anti-obesity Drug Set to Launch

News

The Alberta Diabetes Institute will be at the centre of a new clinical trial for an anti-obesity drug targeting people with rare genetic conditions that contribute to their obesity.

READ MORE

Enhancing the Infection-fighting Potential of Natural Products

News

A team has identified multiple promising new drug candidates to treat antibiotic-resistant infections, including the superbug MRSA.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE